BioSpace News Archive

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter ended December 31, 2023 and provided a corporate update.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company) today reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on the Company’s operations.

argenx announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET to discuss its full year 2023 financial results and provide a fourth quarter business update.

Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, decisively continued on its profitable growth course in the financial year 2023 with an organic revenue growth of 10.4% and a strong adjusted EBITDA growth of 17.5%.

Photocure ASA announces that its partner Asieris Pharmaceuticals has communicated that the international multicenter Phase III clinical study of Cevira®, the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions, will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia, held March 13-16 in Stockholm, Sweden:

Greenwich LifeSciences, Inc. provided the following update on the expansion of the clinical trial into Europe.

Theravance Biopharma, Inc. will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5 at 10:30 am ET.

Immunocore Holdings plc announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to investigate Immunocore’s ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb’s nivolumab, in first-line advanced cutaneous melanoma.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.

Chimerix (NASDAQ:CMRX) today announced that it will host a live conference call and audio webcast on Thursday, February 29, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2023, and to provide a business overview.